SynthesisInternational urology and nephrology2011
Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis.
Synthesis in International urology and nephrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 5 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis.Digestive diseases and sciences · 2019Guideline
- Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.The Cochrane database of systematic reviews · 2017Pooled it
- Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis.BMC gastroenterology · 2015Pooled it
- Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis.PloS one · 2015Pooled it
- Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.PloS one · 2014Pooled it
- Practice guidance for the use of terlipressin for liver cirrhosis-related complications.Therapeutic advances in gastroenterology · 2022Article
- Renal Dysfunction in Cirrhosis: Critical Care Management.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2021Article
- Pharmacological treatment of hepatorenal syndrome: a network meta-analysis.Gastroenterology report · 2020Article
- Prevalence and short-term outcome of hepatorenal syndrome: A 9-year experience in a high-complexity hospital in Colombia.PloS one · 2020Article
- Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.United European gastroenterology journal · 2019Observational
- Biomarkers of Acute and Chronic Kidney Disease.Annual review of physiology · 2019Review
- Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects.Therapeutics and clinical risk management · 2019Review
- Feasability of Introducing a Thioether Ring in Vasopressin byFrontiers in microbiology · 2019Article
- New Developments in Hepatorenal Syndrome.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2018Review
- [The importance of hyperdynamic circulation in the progression of liver cirrhosis and its therapeutic strategies].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017Article
- Perspective on Clinical Application of Biomarkers in AKI.Journal of the American Society of Nephrology : JASN · 2017Review
- Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus.World journal of hepatology · 2016Article
- Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome.World journal of gastrointestinal pharmacology and therapeutics · 2015Article
- Urinary biomarkers and progression of AKI in patients with cirrhosis.Clinical journal of the American Society of Nephrology : CJASN · 2014Article
- Renal dysfunction in patients with cirrhosis: Where do we stand?World journal of gastrointestinal pharmacology and therapeutics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundHepatorenal syndrome (HRS) is a common complication in patients with cirrhosis or fulminant liver failure. We systematically reviewed the benefits and harms of using terlipressin, a novel vasoconstricting agent in patients with HRS.
methodsWe searched MEDLINE, SCOPUS, and conference proceedings for relevant trials of terlipressin. Results were summarized using the random-effects model.
resultsEight trials (320 participants) were included. When compared with placebo, terlipressin-treated patients had higher HRS reversal (odds ratio [OR] 7.47, 95% confidence interval [CI] 3.17-17.59), mean arterial pressure (weighted mean difference [WMD] 11.26 mmHg, 95% CI 1.52-21), and urine output. There was a significant increase in ischemic adverse events with terlipressin when compared to placebo. There was mild-to-moderate heterogeneity in these analyses. There was no significant difference between terlipressin and noradrenaline in HRS reversal (OR 1.23, 95% CI, 0.43-3.54), mean arterial pressure, and urine output. Side-effect profile did not differ between terlipressin and noradrenaline.
conclusionTerlipressin improves HRS reversal and other surrogate outcome measures compared with placebo, but no significant differences for these outcomes were noted when comparing terlipressin and noradrenaline. Terlipressin is a potential therapeutic option for HRS, but larger trials comparing terlipressin to other widely used vasoconstrictors are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.